High Court approves NHS puberty blocker trial for children aged 11 and above

The High Court has approved an NHS trial of puberty blockers for children as young as 11, rejecting a legal challenge that sought to stop the study. The ruling means the NHS can begin recruiting participants within weeks for what it describes as a regulated clinical trial with parental consent.

The court's decision was not a judgment on whether the trial is ethical or the right course of action. Instead, it focused on whether the proper process was followed when the decision to proceed was made. The judge ruled that the NHS had looked at the relevant information and made a rational decision.

Conservative MP Rebecca Paul, who opposed the trial, called the ruling "devastating" and said she hopes an appeal will be considered. She argued that the drugs carry known risks, including impacts on fertility, bone density, and brain development. "We already know there are significant harms with respect to these drugs," she said. "Puberty isn't just about physical maturation of our reproductive system, it's actually about maturation of our brain as well."

The trial is part of a wider effort to address gaps in the evidence base around puberty blockers for children. The Cass review, a major independent inquiry into gender identity services for young people, was launched under the Conservative government in 2020. That review has already led to changes, including a ban on routine prescribing of puberty blockers outside of clinical trials.

The NHS has stressed that only a small number of carefully selected children will take part in the trial, and that it will be closely monitored. Supporters of the trial argue that it is a safer way to study the effects of the drugs than allowing unregulated access. Critics, however, maintain that it is wrong to give such drugs to physically healthy children when the long-term consequences are not fully understood.